{"id":6230,"text":"            The percentage inhibition of MenoAct851 on CYP450 showed a statistically significant difference when compared to Ketoconazole in ethanol Concentration-dependent CYP450 inhibition was found in fluorescence screening assay by the MenoAct851 MenoAct851 showed a weaker inhibitory potential on CYP3A4 and CYP2D6 when compared to Ketoconazole and Quinidine respectively.","label":[[41,51,"Herb name"],[55,62,"Target"],[125,138,"Drug"],[173,180,"Target"],[240,251,"Herb name"],[251,262,"Herb name"],[302,309,"Target"],[313,320,"Target"],[337,350,"Drug"],[354,364,"Drug"]],"Comments":[]}
{"id":6231,"text":"MenoAct851 is likely to affect the exposure of Simvastatin when co-administered MenoAct851 (Varanasi BioResearch Pvt.","label":[[0,11,"Herb name"],[47,59,"Drug"],[80,91,"Herb name"]],"Comments":[]}
{"id":6232,"text":"Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.","label":[[80,99,"Pathology"]],"Comments":[]}
{"id":6233,"text":"The present study aims to evaluate the drug interaction potential of MenoAct851 to inhibit cytochrome (CY) P450 in vitro in rats, and to measure its effects on simvastatin pharmacokinetic parameters in healthy human volunteers.","label":[[69,80,"Herb name"],[90,112,"Study"],[160,172,"Drug"],[202,210,"Pathology"]],"Comments":[]}
{"id":6234,"text":"CYP450-carbon monoxide assay of MenoAct851 was performed in rat liver microsomes to calculate the percentage inhibition.","label":[[32,43,"Herb name"]],"Comments":[]}
{"id":6235,"text":"Fluorometric assays of CYP3A4 and CYP2D6 determined half maximal inhibitory concentration value.","label":[],"Comments":[]}
{"id":6236,"text":"A double-blind, randomized, placebo-controlled drug interaction study of MenoAct851 was conducted in 24 healthy adult female volunteers aged 25 to 50 years.","label":[[0,70,"Study"],[73,84,"Herb name"],[101,124,"Cohort"],[118,125,"Sex"],[140,156,"Age"]],"Comments":[]}
{"id":6237,"text":"The selected volunteers were randomized to receive placebo or MenoAct851 500 mg BID PO for 14 days.","label":[[51,59,"Drug"],[61,72,"Herb name"],[72,79,"Amount"],[91,98,"Duration"]],"Comments":[]}
{"id":6238,"text":"On the 15th day, each group received 40 mg single-dose simvastatin.","label":[[37,42,"Amount"],[42,54,"Frequency"],[55,66,"Drug"]],"Comments":[]}
{"id":6239,"text":"Blood samples were drawn at different intervals to measure simvastatin pharmacokinetic parameters.","label":[[59,71,"Drug"]],"Comments":[]}
{"id":6240,"text":"The mean (SD) CYP450 concentration of the diluted microsome sample was calculated and found to be 0.405 (0.12) nmol\/mg.","label":[[13,34,"Parameter"],[97,118,"Amount"]],"Comments":[]}
{"id":6241,"text":"The inhibitory potential of MenoAct851 (41.16% [1.24%]) was found to be less than ketoconazole.","label":[[28,39,"Herb name"],[82,94,"Drug"]],"Comments":[]}
{"id":6242,"text":"Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) µg\/mL and 15.24 (0.58) µg\/mL, respectively, but they were higher than respective positive controls.","label":[[48,59,"Herb name"],[62,69,"Target"],[73,80,"Target"],[85,104,"Amount"],[108,126,"Amount"]],"Comments":[]}
{"id":6243,"text":"There was no statistically significant difference between MenoAct851 and placebo groups concerning the pharmacokinetic parameters such as C MenoAct851 produced weaker interaction potential with CYP3A4 and CYP2D6 substrates based on in vitro assays, but the findings of clinical pharmacokinetic analysis indicate that MenoAct851 increased the AUC of simvastatin and simvastatin hydroxy acid.","label":[[58,69,"Herb name"],[73,81,"Drug"],[140,151,"Herb name"],[193,200,"Target"],[205,212,"Target"],[317,328,"Herb name"],[342,346,"Parameter"],[349,361,"Drug"],[365,389,"Drug"]],"Comments":[]}
{"id":6244,"text":"Therefore, coadministration of MenoAct851 might lead to drug-herb interaction, thereby affecting the therapeutic effect of CYP3A4 substrates.","label":[[31,42,"Herb name"],[123,130,"Target"]],"Comments":[]}
{"id":6245,"text":"(Curr Ther Res Clin Exp.","label":[],"Comments":[]}
{"id":6246,"text":"2020; 81:XXX–XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.","label":[[32,42,"Pathology"],[123,135,"Pathology"],[137,149,"Pathology"],[151,169,"Pathology"],[171,189,"Pathology"],[191,205,"Pathology"],[207,218,"Pathology"],[224,242,"Pathology"]],"Comments":[]}
{"id":6247,"text":"PHFs use is more common in developing countries because of easy accessibility, availability, affordability, and societal acceptability  The MenoAct851 formulation could increase the potential for an herb-drug interaction when it is coadministered with an allopathic medication if the herbal product affects the allopathic drug's metabolism.","label":[[139,150,"Herb name"]],"Comments":[]}
{"id":6248,"text":"CYP450 enzymes play a significant role in the Phase I oxidative metabolism of a wide variety of exogenous chemicals, including drugs; carcinogens; toxins; and endogenous compounds such as steroids, fatty acids, and prostaglandins.","label":[[0,7,"Target"],[134,145,"Drug"],[147,153,"Drug"],[159,229,"Drug"]],"Comments":[]}
{"id":6249,"text":"Isoforms of CYP450 such as CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 are primarily responsible for metabolizing a majority of the drugs used to treat human beings.","label":[[12,18,"Target"],[27,33,"Target"],[35,41,"Target"],[43,49,"Target"],[51,58,"Target"],[64,71,"Target"]],"Comments":[]}
{"id":6250,"text":"MenoAct851is a novel PHF developed at the National Facility for Tribal and Herbal Medicine, Banaras Hindu University, Varanasi, India, in collaboration with Interdisciplinary Institute of Indian System of Medicine and SRM Institute of Science and Technology, Chennai, India, for managing menopause symptoms.","label":[[0,10,"Herb name"],[188,195,"Ethnic group"]],"Comments":[]}
{"id":6251,"text":"The formulation was put into capsule doses from freeze-dried, hydro-alcoholic D bulbifera tuber extracts, T arjuna bark, B arundinacea leaves, and W somnifera roots through a memorandum of understanding with a traditional health practitioner using high ethical standards.","label":[[62,104,"Extraction process"],[77,95,"Herb name"],[106,119,"Herb name"],[120,142,"Herb name"],[147,158,"Herb name"],[159,165,"Herb part"]],"Comments":[]}
{"id":6252,"text":"All of the chemicals and solvents for the preparation of rat liver microsomes and CYP450-carbon monoxide complex assay were of analytical grade (potassium chloride [catalog No.","label":[],"Comments":[]}
{"id":6253,"text":"P9333], and sodium hydrosulfite [catalog No.","label":[],"Comments":[]}
{"id":6254,"text":"71699]), and purchased from Sigma-Aldrich, Mumbai, India.","label":[],"Comments":[]}
{"id":6255,"text":"Vivid CYP450 Screening Kit and Vivid Substrates were purchased from Invitrogen Drug Discovery Solutions (Waltham, Massachusetts).","label":[],"Comments":[]}
{"id":6256,"text":"Vivid CYP3A4 Red (catalog No.","label":[],"Comments":[]}
{"id":6257,"text":"P2856) and Vivid CYP2D6 Blue (catalog No.","label":[],"Comments":[]}
{"id":6258,"text":"P2972) screening kits included baculosome respective isozymes and nicotinamide adenine dinucleotide phosphate-P450 reductase; regeneration system glucose-6-phosphate; glucose-6-phosphate dehydrogenase and nicotinamide adenine dinucleotide phosphate were used for the study.","label":[],"Comments":[]}
{"id":6259,"text":"Ninety-six well black, flat-bottom, polystyrene, untreated microplate were obtained from Corning (Corning, New York).","label":[],"Comments":[]}
{"id":6260,"text":"Ketoconazole was obtained as a gift sample from M\/s Micro Labs Pvt Ltd, Hosur, Tamil Nadu, India, and quinidine was obtained as a gift sample from M\/s Trigenesis Life Sciences Pvt Ltd, Bangalore, Karnataka, India.","label":[[0,13,"Drug"],[102,112,"Drug"]],"Comments":[]}
{"id":6261,"text":"LC-MS grade methanol (catalog No.","label":[],"Comments":[]}
{"id":6262,"text":"34860-2.5L-R) and ammonium acetate (catalog No.","label":[],"Comments":[]}
{"id":6263,"text":"V800034) were used for the pharmacokinetic parameters study.","label":[[26,59,"Study"]],"Comments":[]}
{"id":6264,"text":"The probe drug, simvastatin, and the internal standard, lovastatin, were obtained from Mankind Pharmaceuticals Pvt Ltd, Bangalore, India.","label":[[16,27,"Drug"],[56,66,"Drug"]],"Comments":[]}
{"id":6265,"text":"Liver microsomes were isolated from male Wistar rats weighing 200 to 250 g, based on the method described by Pandit et al  High throughput screening assays were performed in black 96-well microplates.","label":[],"Comments":[]}
{"id":6266,"text":"Fluorescence readings were obtained on BioTekFLx 800 fluorescence microplate reader (BioTek, Winooski, Vermont) using appropriate excitation\/emission wavelength (λ).","label":[],"Comments":[]}
{"id":6267,"text":"The assay was performed according to a protocol provided by Invitrogen Drug Discovery Solutions.","label":[],"Comments":[]}
{"id":6268,"text":"All measurements were performed in triplicate.","label":[],"Comments":[]}
{"id":6269,"text":"Product formation from the fluorogenic probes was determined from the fluorescence data at 7 different concentrations of the inhibitors and tests.","label":[],"Comments":[]}
{"id":6270,"text":"The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.","label":[],"Comments":[]}
{"id":6271,"text":"476\/IEC\/2013) and the study was conducted in accordance with the Declaration of Helsinki in its revised edition, the Guidelines of Good Clinical Practice (CPMP\/ICH\/135\/95), and directives 2001\/20\/EC and 2005\/28\/EC and with international and local regulatory requirements.","label":[],"Comments":[]}
{"id":6272,"text":"Following a full explanation of the study, volunteers provided written consent to participate.","label":[],"Comments":[]}
{"id":6273,"text":"Volunteers were compensated per Institutional Ethics Committee (IEC) guidelines.","label":[],"Comments":[]}
{"id":6274,"text":"Twenty-four female volunteers who were healthy, nonsmokers, had undergone the tubal ligation method of contraception, tested negative for alcohol and drug abuse, aged between 25 and 50 years, and had a body mass index of 18 to 29, were included in this study.","label":[[0,30,"Cohort"],[12,19,"Sex"],[175,190,"Age"],[201,218,"Parameter"],[221,229,"Amount"]],"Comments":[]}
{"id":6275,"text":"Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease\/disorder.","label":[[88,231,"Pathology"]],"Comments":[]}
{"id":6276,"text":"A volunteer also was excluded if she had a psychological; psychiatric; or metabolic disorder, including eating disorders; or if she had experienced any acute illness within the previous 4 weeks.","label":[[43,91,"Pathology"],[103,121,"Pathology"],[152,165,"Pathology"]],"Comments":[]}
{"id":6277,"text":"Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.","label":[[0,7,"Sex"],[73,107,"Parameter"],[188,196,"Duration"]],"Comments":[]}
{"id":6278,"text":"The volunteers were forbidden from using any medications or herbal products for 15 days before and during the study.","label":[[80,87,"Duration"]],"Comments":[]}
{"id":6279,"text":"Drugs that are known to cause enzyme induction or inhibition and grapefruit juice were not allowed for the 30 days leading up to the study.","label":[[107,114,"Duration"]],"Comments":[]}
{"id":6280,"text":"Consuming coffee, tea, alcohol, and cola drinks were not allowed during the study.","label":[],"Comments":[]}
{"id":6281,"text":"Nicotine use was assessed by the Fagerstrom test for nicotine dependence.","label":[],"Comments":[]}
{"id":6282,"text":"The study was a double-blind, randomized, placebo-controlled, single-dose simvastatin and multiple-dose MenoAct851 drug-herb interaction study.","label":[[16,60,"Study"],[61,74,"Frequency"],[74,86,"Drug"],[104,115,"Herb name"]],"Comments":[]}
{"id":6283,"text":"The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.","label":[[43,51,"Drug"],[105,116,"Herb name"],[129,136,"Amount"],[143,151,"Duration"]],"Comments":[]}
{"id":6284,"text":"Double-blinded treatments were allocated using sequentially numbered drug containers.","label":[],"Comments":[]}
{"id":6285,"text":"The randomization code was concealed to avoid selection bias, which secured the trial's blinding codes.","label":[],"Comments":[]}
{"id":6286,"text":"On day 15 of the trial, each group was received a 40 mg single-dose simvastatin.","label":[[50,55,"Amount"],[55,67,"Frequency"],[68,79,"Drug"]],"Comments":[]}
{"id":6287,"text":"Per the schedule, the selected volunteers fasted overnight on those days.","label":[],"Comments":[]}
{"id":6288,"text":"As soon as the volunteers assembled, Venflon Paul Medical Systems, Chennai, India was inserted by vein puncture into each volunteer's forearm vein before the drug administration, and 5 mL blood was drawn at T Following the administered dose of simvastatin, blood samples were taken at the following intervals: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after the administration of the drug, including predose (total of 13 samples, each 3 mL).","label":[[244,255,"Drug"]],"Comments":[]}
{"id":6289,"text":"All of the samples were collected by trained personnel using an intravenous cannula placed in a forearm\/arm vein using prelabeled vacutainers containing K Simvastatin and simvastatin hydroxy acid with lovastatin as an internal standard were determined in plasma by validated LC-MS method.","label":[[155,167,"Drug"],[171,195,"Drug"],[201,212,"Drug"]],"Comments":[]}
{"id":6290,"text":"An amount of 50 µL internal standard lovastatin was added to tubes containing 200 µL plasma.","label":[[13,18,"Amount"],[37,48,"Drug"]],"Comments":[]}
{"id":6291,"text":"After a thorough vortex mixing for 30 seconds, mixtures were extracted with 2 mL acetonitrile, vortex-mixed for 3 minutes, and centrifuged at 4000 rpm for 10 minutes.","label":[],"Comments":[]}
{"id":6292,"text":"An amount of 1.5 mL of the organic layer was removed to another centrifuge tube and evaporated under a stream of nitrogen gas in the thermostatically controlled water-bath maintained at 40°C until completely dry.","label":[[13,19,"Amount"]],"Comments":[]}
{"id":6293,"text":"The dried residue obtained was dissolved in 100 µL methanol, vortex-mixed for 2 minutes, centrifuged at 4000 rpm for 10 minutes, and 20 µL of the supernatant liquid was injected into the LC-MS system.","label":[],"Comments":[]}
{"id":6294,"text":"The created strategy was linear in the fixation scope of 0.100 to 74.626 ng\/mL for simvastatin and 0.100 to 48.971 ng\/mL for simvastatin hydroxy acid, with connection coefficient more prominent than 0.99 for both analytes.","label":[[83,95,"Drug"],[125,149,"Drug"]],"Comments":[]}
{"id":6295,"text":"The approach demonstrated considerable reproducibility for all analytes, with intra- and interday precision with <5.6%, and intra- and interday precision of ±10.1% of nominal values.","label":[],"Comments":[]}
{"id":6296,"text":"Quantitation was performed by multiple reaction monitoring mode of precursor–production transitions at m\/z 435.2 → 281.2 for simvastatin, m\/z 412.3 → 286.3 for simvastatin hydroxy acid at 150 ms per transition.","label":[[125,136,"Drug"],[159,184,"Drug"]],"Comments":[]}
{"id":6297,"text":"Limit of quantitation was 0.24 ng\/mL and 0.22 ng\/mL for simvastatin and simvastatin hydroxy acid, respectively.","label":[[56,68,"Drug"],[71,96,"Drug"]],"Comments":[]}
{"id":6298,"text":"Simvastatin and simvastatin hydroxy acid concentrations were calculated for each volunteer when simvastatin was dosed with the placebo, and in combination with MenoAct851 formulation, a noncompartmental method was applied using WinNonlin professional version 5.0.1 (Pharsight Corp, Mountain View, California).","label":[[0,12,"Drug"],[16,41,"Drug"],[96,108,"Drug"],[127,134,"Drug"],[160,171,"Herb name"]],"Comments":[]}
{"id":6299,"text":"The key pharmacokinetic parameters calculated for simvastatin and simvastatin hydroxy acid included C The results are presented as the mean (standard deviation).","label":[[50,62,"Drug"],[66,90,"Drug"]],"Comments":[]}
{"id":6300,"text":"IC The mean (SD) concentration of protein in isolated rat liver microsome was 6.2 (0.81) mg\/mL (n = 3).","label":[],"Comments":[]}
{"id":6301,"text":"CYP450-carbon monoxide complex assay was used to assess the inhibitory potential of MenoAct851.","label":[[84,94,"Herb name"]],"Comments":[]}
{"id":6302,"text":"The mean (SD) CYP450 concentration of the diluted microsome sample was calculated and was found to be 0.405 (0.12) nmol\/mg protein (n = 3).","label":[[14,35,"Parameter"],[102,123,"Amount"]],"Comments":[]}
{"id":6303,"text":"Two different solvents ethanol and dimethyl sulfoxide were used for CYP450 inhibition assay to confirm the solvent effect.","label":[[68,75,"Target"]],"Comments":[]}
{"id":6304,"text":"Percentage inhibition of MenoAct851 versus positive controls (n = 3).","label":[[25,36,"Herb name"]],"Comments":[]}
{"id":6305,"text":"Values are expressed in mean (SD).","label":[],"Comments":[]}
{"id":6306,"text":"ANOVA followed by Dunnett's multiple comparison test.","label":[],"Comments":[]}
{"id":6307,"text":"DMSO = dimethyl sulfoxide.","label":[],"Comments":[]}
{"id":6308,"text":"*Level of significance at P < 0.05.","label":[],"Comments":[]}
{"id":6309,"text":"MenoAct851 and positive controls were assayed between concentrations ranging from 1.5 to 25 μg\/mL.","label":[[0,11,"Herb name"],[82,98,"Amount"]],"Comments":[]}
{"id":6310,"text":"All samples were assayed in triplicate, the end point mode was selected, and IC Half maximal inhibitory concentration (IC Values are expressed as mean (SD).","label":[],"Comments":[]}
{"id":6311,"text":"Concentration dependent inhibitory effect of MenoAct851 and positive controls dimethyl sulfoxided (DMSO).","label":[[45,56,"Herb name"]],"Comments":[]}
{"id":6312,"text":"(A) cytochrome (CY) P3A4.","label":[[4,25,"Target"]],"Comments":[]}
{"id":6313,"text":"(B) CYP2D6.","label":[[4,10,"Target"]],"Comments":[]}
{"id":6314,"text":"Values are expressed as mean (SD) (n = 3).","label":[],"Comments":[]}
{"id":6315,"text":"LC-MS chromatograms of standard simvastatin, plasma-spiked simvastatin, and the volunteers’ plasma samples are shown in Figure 3.","label":[[32,43,"Drug"],[59,70,"Drug"]],"Comments":[]}
{"id":6316,"text":"The main pharmacokinetic parameters of simvastatin and its hydroxy acid metabolite for the 24 female volunteers were determined by noncompartmental model analyses listed in Tables 2 and 3.","label":[[39,51,"Drug"],[90,112,"Cohort"],[94,101,"Sex"]],"Comments":[]}
{"id":6317,"text":"The mean (SD) for each parameter was given for the 2 groups in which simvastatin was administered.","label":[[69,81,"Drug"]],"Comments":[]}
{"id":6318,"text":"The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure 4.","label":[[39,50,"Drug"],[67,91,"Drug"],[115,126,"Drug"]],"Comments":[]}
{"id":6319,"text":"Maximal simvastatin levels were observed in the placebo group after 1.32 (0.44) hours and 1.92 (0.26) hours in MenoAct851 group (Figure 5).","label":[[8,20,"Drug"],[48,56,"Drug"],[111,122,"Herb name"]],"Comments":[]}
{"id":6320,"text":"Maximal simvastatin hydroxy acid levels were observed in placebo group after 1.28 (0.66) hours and 1.51 (0.24) hours in MenoAct851 group (Figure 6).","label":[[8,32,"Drug"],[57,65,"Drug"],[120,131,"Herb name"]],"Comments":[]}
{"id":6321,"text":"Simvastatin and simvastatin hydroxy acid's peak plasma concentration in the placebo group was 17.51 (2.65) ng\/mL and 12.58 (0.88) ng\/mL, respectively.","label":[[0,12,"Drug"],[0,69,"Parameter"],[16,42,"Drug"],[76,84,"Drug"],[94,112,"Amount"],[117,135,"Amount"]],"Comments":[]}
{"id":6322,"text":"The peak plasma concentration of simvastatin 18.44 (1.56) ng\/mL and simvastatin hydroxy acid 14.11 (2.12) ng\/mL in MenoAct851 group was slightly higher than the placebo group.","label":[[3,29,"Parameter"],[33,45,"Drug"],[45,63,"Amount"],[67,92,"Drug"],[93,111,"Amount"],[115,126,"Herb name"],[161,169,"Drug"]],"Comments":[]}
{"id":6323,"text":"Chromatogram.","label":[],"Comments":[]}
{"id":6324,"text":"(A) Standard simvastatin.","label":[[13,24,"Drug"]],"Comments":[]}
{"id":6325,"text":"(B) Blank plasma spiked with simvastatin.","label":[[29,40,"Drug"]],"Comments":[]}
{"id":6326,"text":"x-axis = runtime; y-axis = mV.","label":[],"Comments":[]}
{"id":6327,"text":"Pharmacokinetic parameters of simvastatin with placebo and in combination with MenoAct851 (Varanasi BioResearch Pvt.","label":[[30,42,"Drug"],[47,55,"Drug"],[79,90,"Herb name"]],"Comments":[]}
{"id":6328,"text":"Ltd., Varanasi, India) formulation.","label":[],"Comments":[]}
{"id":6329,"text":"Values are expressed as mean (SD).","label":[],"Comments":[]}
{"id":6330,"text":"A difference was considered significant at P < 0.05.","label":[],"Comments":[]}
{"id":6331,"text":"Pharmacokinetic parameters of simvastatin hydroxy acid with placebo and in combination with MenoAct851 (Varanasi BioResearch Pvt.","label":[[29,54,"Drug"],[60,68,"Drug"],[92,103,"Herb name"]],"Comments":[]}
{"id":6332,"text":"Ltd., Varanasi, India) formulation.","label":[],"Comments":[]}
{"id":6333,"text":"Values are expressed as mean (SD).","label":[],"Comments":[]}
{"id":6334,"text":"A difference was considered significant at P < 0.05.","label":[],"Comments":[]}
{"id":6335,"text":"Chromatogram.","label":[],"Comments":[]}
{"id":6336,"text":"(A) Internal standard lovastatin.","label":[[22,32,"Drug"]],"Comments":[]}
{"id":6337,"text":"(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.","label":[[48,64,"Frequency"],[68,73,"Amount"],[74,85,"Drug"]],"Comments":[]}
{"id":6338,"text":"x-axis = runtime; y-axis = mV.","label":[],"Comments":[]}
{"id":6339,"text":"Mean plasma concentration time-profiles of simvastatin after a single oral dose of 40 mg simvastatin with placebo and after pretreatment with 500 mg MenoAct851 BID PO for 14 days.","label":[[0,39,"Parameter"],[43,55,"Drug"],[63,79,"Frequency"],[82,89,"Amount"],[89,101,"Drug"],[106,114,"Drug"],[141,149,"Amount"],[149,160,"Herb name"],[171,178,"Duration"]],"Comments":[]}
{"id":6340,"text":"Mean plasma concentration time-profiles of simvastatin hydroxy acid after a single oral dose of 40 mg simvastatin with placebo and after pretreatment with 500 mg MenoAct851 BID PO for 14 days.","label":[[0,40,"Parameter"],[43,68,"Drug"],[76,93,"Frequency"],[95,101,"Amount"],[102,114,"Drug"],[119,127,"Drug"],[154,161,"Amount"],[162,173,"Herb name"],[184,191,"Duration"]],"Comments":[]}
{"id":6341,"text":"MenoAct851 was well tolerated throughout the study and also when coadministered with simvastatin.","label":[[0,11,"Herb name"],[85,96,"Drug"]],"Comments":[]}
{"id":6342,"text":"No serious adverse events occurred.","label":[[2,25,"Pathology"]],"Comments":[]}
{"id":6343,"text":"The only adverse events reported by more than 1 volunteer during MenoAct851 or placebo treatment period were nausea and abdominal discomfort.","label":[[9,23,"Pathology"],[65,76,"Herb name"],[79,87,"Drug"],[109,116,"Pathology"],[120,140,"Pathology"]],"Comments":[]}
{"id":6344,"text":"All mean laboratory parameters for serum chemistry, hematology, and urinalysis remained within reference range during their discharge.","label":[],"Comments":[]}
{"id":6345,"text":"There were no remarkable findings in the vital signs, echocardiograms, physical examinations, visual acuity tests, and slit-lamp examinations in this study.","label":[],"Comments":[]}
{"id":6346,"text":"None of the adverse events resulted in discontinuation from the study.","label":[],"Comments":[]}
{"id":6347,"text":"Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.","label":[[171,186,"Parameter"]],"Comments":[]}
{"id":6348,"text":"Numerous case studies have described harmful herb-drug interactions that could lead to morbidity or mortality.","label":[],"Comments":[]}
{"id":6349,"text":"In the present study, an approach is made to evaluate the interaction potential of MenoAct851 on CYP450, through rat liver microsomes and high throughput fluorescence screening assays.","label":[[83,94,"Herb name"],[97,103,"Target"]],"Comments":[]}
{"id":6350,"text":"Orally administered medicinal products were mostly metabolized by gut flora before being absorbed into the systematic circulation.","label":[],"Comments":[]}
{"id":6351,"text":"There was no statistically significant difference between the MenoAct851 and the placebo groups with respect to the mean pharmacokinetic parameters like C Lack of nicotine estimation in the volunteers was the limitation of the clinical pharmacokinetic parameters study.","label":[[62,73,"Herb name"],[81,89,"Drug"]],"Comments":[]}
{"id":6352,"text":"This study reports only the effects of MenoAct851 on CYP3A4 and CYP2D6 isoforms, the effects on other isoforms remains unknown.","label":[[39,50,"Herb name"],[53,60,"Target"],[64,71,"Target"]],"Comments":[]}
{"id":6353,"text":"Further tests on other CY isoforms and transporters should be conducted to determine whether MenoAct851 has any additional effects on allopathic medicines’ metabolism and pharmacokinetic parameters.","label":[[93,104,"Herb name"]],"Comments":[]}
{"id":6354,"text":"Coadministered, repeat 500-mg doses of MenoAct851 with a single 40-mg dose of simvastatin resulted in significant change in the plasma simvastatin and simvastatin hydroxy acid AUC, indicating an inhibitory effect of MenoAct851 on CYP3A4 activity.","label":[[22,30,"Amount"],[39,50,"Herb name"],[56,74,"Frequency"],[63,69,"Amount"],[78,90,"Drug"],[135,147,"Drug"],[150,175,"Drug"],[176,179,"Parameter"],[216,227,"Herb name"],[229,236,"Target"]],"Comments":[]}
{"id":6355,"text":"Thus, MenoAct851 is likely to affect the exposure of CYP3A4 substrates following coadministration.","label":[[6,17,"Herb name"],[53,60,"Target"]],"Comments":[]}
{"id":6356,"text":"Accordingly, caution should be taken when MenoAct851 formulations are used in combination with allopathic drugs metabolized by CYP3A4.","label":[[42,53,"Herb name"],[127,133,"Target"]],"Comments":[]}
{"id":6357,"text":"Dr Govind Prasad Dubey holds the patent for MenoAct851.","label":[[44,54,"Herb name"]],"Comments":[]}
{"id":6358,"text":"The authors have indicated that they have no other conflicts of interest regarding the content of this article.","label":[],"Comments":[]}
{"id":6359,"text":"All the authors contributed equally.","label":[],"Comments":[]}
{"id":6360,"text":"The authors thank the Department of Science and Technology, Government of India (grant No.","label":[],"Comments":[]}
{"id":6361,"text":": VI-D&P\/372\/10-11\/TDT) for their financial assistance and support.","label":[],"Comments":[]}
{"id":6362,"text":"The authors also thank Dr K. Ananth Kumar, Dr I. Jyothi, and Dr K. Vasanth from Interdisciplinary Institute of Indian System of Medicine Department for their support throughout the study.","label":[],"Comments":[]}
{"id":6363,"text":"In addition, the authors thank Dr S. Sheller-Miller, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas, for assisting with the English in the manuscript as well as Editing Press for final English language copyediting.","label":[],"Comments":[]}
